Bristol Myers Squibb Announces Updated Guidance For BREYANZI Chimeric Antigen Receptor T Cell Therapy Includes Lowered Recommended Duration For Patients To Remain In Close Proximity To Specialized Treatment Centre From 28 Days To 14 Days

뉴스 본문을 불러오고 있어요.

Bristol Myers Squibb Announces Updated Guidance For BREYANZI Chimeric Antigen Receptor T Cell Therapy Includes Lowered Recommended Duration For Patients To Remain In Close Proximity To Specialized Treatment Centre From 28 Days To 14 Days | 웨이프 WAPE

Bristol Myers Squibb Announces Updated Guidance For BREYANZI Chimeric Antigen Receptor T Cell Therapy Includes Lowered Recommended Duration For Patients To Remain In Close Proximity To Specialized Treatment Centre From 28 Days To 14 Days

기사 요약

관련 종목

댓글 —